Calcitonin
Mechanism :
Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals. Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized.
Indication :
- Osteogenesis imperfecta
- Hypercalcemia
Contraindications :
Clinical allergy to calcitonin-salmon. For patients with suspected sensitivity to calcitonin, skin testing should be considered prior to treatment utilizing a dilute, sterile solution of a calcitonin-salmon injectable product.
Dosing :
Osteogenesis imperfecta:
>6 months: IM, SC: 2 units/kg/dose 3 times/week.
Adverse Effect :
Flushing of face, edema, dizziness, headache, chills, rash, nausea, vomiting, diarrhea, anorexia, metallic taste, inflammatory reactions at injection site, weakness, tingling of palms and soles, back and joint pain, diuresis, shortness of breath, hypersensitivity reactions.
Interaction :
Cardiac glycosides: Calcitonin may cause serum calcium levels to fall transiently to below normal levels, and therefore dose adjustment of cardiac glycosides may be necessary.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
20-50 | Dose as in normal renal function |
10-20 | Dose as in normal renal function |
<10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
CAPD | Unlikely to be dialysed. Dose as in normal renal function |
HD | Unlikely to be dialysed. Dose as in normal renal function |
HDF/High flux | Unlikely to be dialysed. Dose as in normal renal function |
CAV/VVHD | Unlikely to be dialysed. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are recommended.